Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Routinely available
SMC (SMC2526)
11/10/2023
Indication
As monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma and who have undergone complete resection.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with local or regional guidance
Formulation
Concentrate for solution for infusion
Comments
October 2023 - Routinely available in line with local or regional guidance. Approved for adults > 18 years, awaiting information from paediatric oncology team.